Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study

Ozanimod is a novel, selective, oral sphingosine‐1‐phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease. This randomized, double‐blind, placebo‐controlled, positive‐controlled, parallel‐group thorough QT study characterized the effects of ozanim...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Jonathan Q., Hartung, Jeffrey P., Olson, Allan D., Mendzelevski, Boaz, Timony, Gregg A., Boehm, Marcus F., Peach, Robert J., Gujrathi, Sheila, Frohna, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901414/
https://www.ncbi.nlm.nih.gov/pubmed/28783871
http://dx.doi.org/10.1002/cpdd.383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901414/
https://www.ncbi.nlm.nih.gov/pubmed/28783871
http://dx.doi.org/10.1002/cpdd.383

Ejemplares similares